Gene expression profiling predicts relapse‐free and overall survival in newly diagnosed myeloma patients treated with novel therapies.

Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies In addition, the LR FISH/HR GEP had a relapse rate at 12 months of 30% (3/12 patients) I versus i 0% in patients with LR GEP/HR FISH (0/8 patients; B Table b IA B ) b . Patients with HR GEP/HR FISH demonstrated reduced RFS and OS when compared to LR GEP/FISH with HR GEP being the best predictor of early RFS. For example, patients with HR GEP had a death rate due to multiple myeloma (MM) of 21% (HR GEP/HR FISH), 25% (HR GEP/LR FISH), 0% (LR GEP/HR FISH) and 6% (LR GEP/LR FISH) ( I P i = 0-03; B Table b IB B ) b . [Extracted from the article]